<p>根据公司在最近向美国证券交易委员会（SEC）披露的信息，Donald L. Hagan LLC 在第三季度购买了 Bristol Myers Squibb Company（纽约证券交易所代码：BMY - 免费报告）的新股份。该基金购买了 20,550 股生物制药公司的股票，价值约为 927,000 美元。</p>
<ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
<p>其他大型投资者最近也对该公司的持股进行了调整。Brighton Jones LLC 在第四季度将其在 Bristol Myers Squibb 的股份增加了 33.4%。Brighton Jones LLC 现在拥有 19,728 股生物制药公司的股票，价值为 1,116,000 美元，此前在上个季度又购买了 4,935 股。Jump Financial LLC 在第一季度购买了 Bristol Myers Squibb 的新股份，价值约为 438,000 美元。Ieq Capital LLC 在第一季度将其在 Bristol Myers Squibb 的持股增加了 27.6%。Ieq Capital LLC 现在拥有 172,523 股生物制药公司的股票，价值为 10,522,000 美元，此前在上个季度又购买了 37,362 股。CreativeOne Wealth LLC 在第一季度将其在 Bristol Myers Squibb 的股份提高了 6.4%。CreativeOne Wealth LLC 现在拥有 32,748 股生物制药公司的股票，价值为 1,997,000 美元，此前在此期间又购买了 1,969 股。最后，Transamerica Financial Advisors LLC 在第一季度将其在 Bristol Myers Squibb 的持股提高了 1.0%。Transamerica Financial Advisors LLC 现在拥有 24,065 股生物制药公司的股票，价值为 1,468,000 美元，此前在上个季度又购买了 241 股。机构投资者和对冲基金持有该公司 76.41% 的股份。</p>
<p>获取 <strong>Bristol Myers Squibb</strong> 的提醒：</p>
<h2>Bristol Myers Squibb 股票表现</h2>
<p>纽约证券交易所 BMY 周五开盘价为 54.63 美元。该公司的 50 日移动平均价格为 48.61 美元，200 日移动平均价格为 47.33 美元。Bristol Myers Squibb Company 的 12 个月低点为 42.52 美元，12 个月高点为 63.33 美元。该公司的市值为 1,112 亿美元，市盈率为 18.45，市盈增长比率为 8.37，贝塔系数为 0.29。该公司的速动比率为 1.17，流动比率为 1.27，债务与股本比率为 2.39。</p>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>Bristol Myers Squibb（纽约证券交易所代码：BMY - 获取免费报告）最近一次公布财报是在 10 月 30 日，周四。该生物制药公司报告本季度每股收益为 1.63 美元，超出市场共识预期的 1.52 美元，超出幅度为 0.11 美元。该公司本季度的收入为 122.2 亿美元，而分析师预期为 117.5 亿美元。Bristol Myers Squibb 的净利润率为 12.57%，股本回报率为 76.53%。该公司本季度的收入同比增长了 2.8%。去年同期，该公司每股收益为 1.80 美元。Bristol Myers Squibb 已将其 2025 财年的指导目标设定为每股收益 6.400-6.600 美元。分析师预计 Bristol Myers Squibb Company 在当前年度将发布每股收益 6.74 美元。</p>
<h2>Bristol Myers Squibb 增加股息</h2>
<p>该公司还最近宣布了一项季度股息，将于 2 月 2 日（星期一）支付。1 月 2 日（星期五）登记的股东将获得每股 0.63 美元的股息。这相当于每年 2.52 美元的股息和 4.6% 的股息收益率。除息日期为 1 月 2 日（星期五）。这比 Bristol Myers Squibb 之前的季度股息 0.62 美元有所增加。Bristol Myers Squibb 的股息支付比率目前为 83.78%。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>一些研究分析师最近对该公司发表了看法。Sanford C. Bernstein 在 11 月 3 日（星期一）的一份报告中重申了对 Bristol Myers Squibb 股票的 “市场表现” 评级。华尔街 Zen 在 11 月 8 日（星期六）的一份报告中将 Bristol Myers Squibb 的股票评级从 “买入” 上调至 “强力买入”。Guggenheim 在周二的一份研究报告中重申了对 Bristol Myers Squibb 股票的 “买入” 评级。Weiss Ratings 在 10 月 14 日（星期二）的一份报告中重申了对 Bristol Myers Squibb 股票的 “持有（C-）” 评级。最后，BMO Capital Markets 在 11 月 17 日（星期一）的一份报告中重申了对 Bristol Myers Squibb 股票的 “市场表现” 评级。六位股票研究分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com，该公司目前的平均评级为 “持有”，平均目标价格为 54.62 美元。</p>
<p><strong>阅读我们关于 Bristol Myers Squibb 的最新股票报告</strong></p>
<h2>Bristol Myers Squibb 公司简介</h2>
<p>（免费报告）</p>
<p>Bristol Myers Squibb 是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。该公司的核心业务包括研究与开发、临床开发、制造和商业化多种治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
<p>BMS 的市场产品组合和后期管线反映了对癌症和免疫介导疾病的强烈关注。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Bristol Myers Squibb</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备战争</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票【不是 NVDA】</li>
<li>麦当劳的秘密</li>
<li>来自奇怪的新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 BMY 股票吗？</strong> 访问 HoldingsChannel.com 获取 Bristol Myers Squibb Company（纽约证券交易所代码：BMY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1CTVk?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1CTVk"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

<p>Donald L. Hagan LLC 在第三季度收购了 20,550 股百时美施贵宝，价值约 927,000 美元。其他投资者，包括 Brighton Jones LLC 和 Ieq Capital LLC 也调整了他们在该公司的持仓。百时美施贵宝报告的季度每股收益为 1.63 美元，超出预期，并宣布每股股息增加至 0.63 美元。分析师对该股票的评级不一，平均评级为 “持有”，目标价格为 54.62 美元</p>

<p>Donald L. Hagan LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 20,550 shares of the biopharmaceutical company's stock, valued at approximately $927,000.</p>
<div class="lb-trans"><p>根据公司在最近向美国证券交易委员会（SEC）披露的信息，Donald L. Hagan LLC 在第三季度购买了 Bristol Myers Squibb Company（纽约证券交易所代码：BMY - 免费报告）的新股份。该基金购买了 20,550 股生物制药公司的股票，价值约为 927,000 美元。</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
</div><p>Other large investors also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Jump Financial LLC bought a new position in Bristol Myers Squibb during the first quarter worth about $438,000. Ieq Capital LLC increased its position in Bristol Myers Squibb by 27.6% during the first quarter. Ieq Capital LLC now owns 172,523 shares of the biopharmaceutical company's stock worth $10,522,000 after buying an additional 37,362 shares during the last quarter. CreativeOne Wealth LLC raised its stake in Bristol Myers Squibb by 6.4% in the first quarter. CreativeOne Wealth LLC now owns 32,748 shares of the biopharmaceutical company's stock valued at $1,997,000 after buying an additional 1,969 shares during the period. Finally, Transamerica Financial Advisors LLC lifted its position in shares of Bristol Myers Squibb by 1.0% in the first quarter. Transamerica Financial Advisors LLC now owns 24,065 shares of the biopharmaceutical company's stock valued at $1,468,000 after buying an additional 241 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持股进行了调整。Brighton Jones LLC 在第四季度将其在 Bristol Myers Squibb 的股份增加了 33.4%。Brighton Jones LLC 现在拥有 19,728 股生物制药公司的股票，价值为 1,116,000 美元，此前在上个季度又购买了 4,935 股。Jump Financial LLC 在第一季度购买了 Bristol Myers Squibb 的新股份，价值约为 438,000 美元。Ieq Capital LLC 在第一季度将其在 Bristol Myers Squibb 的持股增加了 27.6%。Ieq Capital LLC 现在拥有 172,523 股生物制药公司的股票，价值为 10,522,000 美元，此前在上个季度又购买了 37,362 股。CreativeOne Wealth LLC 在第一季度将其在 Bristol Myers Squibb 的股份提高了 6.4%。CreativeOne Wealth LLC 现在拥有 32,748 股生物制药公司的股票，价值为 1,997,000 美元，此前在此期间又购买了 1,969 股。最后，Transamerica Financial Advisors LLC 在第一季度将其在 Bristol Myers Squibb 的持股提高了 1.0%。Transamerica Financial Advisors LLC 现在拥有 24,065 股生物制药公司的股票，价值为 1,468,000 美元，此前在上个季度又购买了 241 股。机构投资者和对冲基金持有该公司 76.41% 的股份。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bristol Myers Squibb</strong> 的提醒：</p>
</div><h2>Bristol Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb 股票表现</h2>
</div><p>NYSE BMY opened at $54.63 on Friday. The firm has a 50-day moving average price of $48.61 and a two-hundred day moving average price of $47.33. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a market capitalization of $111.20 billion, a P/E ratio of 18.45, a P/E/G ratio of 8.37 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.</p>
<div class="lb-trans"><p>纽约证券交易所 BMY 周五开盘价为 54.63 美元。该公司的 50 日移动平均价格为 48.61 美元，200 日移动平均价格为 47.33 美元。Bristol Myers Squibb Company 的 12 个月低点为 42.52 美元，12 个月高点为 63.33 美元。该公司的市值为 1,112 亿美元，市盈率为 18.45，市盈增长比率为 8.37，贝塔系数为 0.29。该公司的速动比率为 1.17，流动比率为 1.27，债务与股本比率为 2.39。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analysts' expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business's revenue for the quarter was up 2.8% on a year-over-year basis. During the same period last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.</p>
<div class="lb-trans"><p>Bristol Myers Squibb（纽约证券交易所代码：BMY - 获取免费报告）最近一次公布财报是在 10 月 30 日，周四。该生物制药公司报告本季度每股收益为 1.63 美元，超出市场共识预期的 1.52 美元，超出幅度为 0.11 美元。该公司本季度的收入为 122.2 亿美元，而分析师预期为 117.5 亿美元。Bristol Myers Squibb 的净利润率为 12.57%，股本回报率为 76.53%。该公司本季度的收入同比增长了 2.8%。去年同期，该公司每股收益为 1.80 美元。Bristol Myers Squibb 已将其 2025 财年的指导目标设定为每股收益 6.400-6.600 美元。分析师预计 Bristol Myers Squibb Company 在当前年度将发布每股收益 6.74 美元。</p>
</div><h2>Bristol Myers Squibb Increases Dividend</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb 增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. Bristol Myers Squibb's dividend payout ratio is currently 83.78%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度股息，将于 2 月 2 日（星期一）支付。1 月 2 日（星期五）登记的股东将获得每股 0.63 美元的股息。这相当于每年 2.52 美元的股息和 4.6% 的股息收益率。除息日期为 1 月 2 日（星期五）。这比 Bristol Myers Squibb 之前的季度股息 0.62 美元有所增加。Bristol Myers Squibb 的股息支付比率目前为 83.78%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>A number of research analysts recently weighed in on the company. Sanford C. Bernstein reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wall Street Zen upgraded shares of Bristol Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, November 8th. Guggenheim restated a &#34;buy&#34; rating on shares of Bristol Myers Squibb in a research note on Tuesday. Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Finally, BMO Capital Markets reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Six equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average target price of $54.62.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司发表了看法。Sanford C. Bernstein 在 11 月 3 日（星期一）的一份报告中重申了对 Bristol Myers Squibb 股票的 “市场表现” 评级。华尔街 Zen 在 11 月 8 日（星期六）的一份报告中将 Bristol Myers Squibb 的股票评级从 “买入” 上调至 “强力买入”。Guggenheim 在周二的一份研究报告中重申了对 Bristol Myers Squibb 股票的 “买入” 评级。Weiss Ratings 在 10 月 14 日（星期二）的一份报告中重申了对 Bristol Myers Squibb 股票的 “持有（C-）” 评级。最后，BMO Capital Markets 在 11 月 17 日（星期一）的一份报告中重申了对 Bristol Myers Squibb 股票的 “市场表现” 评级。六位股票研究分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com，该公司目前的平均评级为 “持有”，平均目标价格为 54.62 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Bristol Myers Squibb 的最新股票报告</strong></p>
</div><h2>Bristol Myers Squibb Company Profile</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>Bristol Myers Squibb 是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。该公司的核心业务包括研究与开发、临床开发、制造和商业化多种治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市场产品组合和后期管线反映了对癌症和免疫介导疾病的强烈关注。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Bristol Myers Squibb</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备战争</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票【不是 NVDA】</li>
<li>麦当劳的秘密</li>
<li>来自奇怪的新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 BMY 股票吗？</strong> 访问 HoldingsChannel.com 获取 Bristol Myers Squibb Company（纽约证券交易所代码：BMY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Donald L. Hagan LLC 购买了 20,550 股百时美施贵宝公司（Bristol Myers Squibb）的股票